WASHINGTON - Investors Friday left all doubts aside about InterMune Inc.'s pirfenidone, driving shares of the company up 59.3 percent, despite an FDA review that said the firm's overall Phase III package failed to provide substantial evidence of the drug's efficacy benefit in reducing decline in lung function in patients with idiopathic pulmonary fibrosis (IPF), a progressive fatal disease that affects about 100,000 Americans. (BioWorld Today) Read More
